These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31715457)

  • 1. Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    Arru G; Sechi E; Mariotto S; Zarbo IR; Ferrari S; Gajofatto A; Monaco S; Deiana GA; Bo M; Sechi LA; Sechi GP
    J Neuroimmunol; 2020 Jan; 338():577110. PubMed ID: 31715457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
    Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
    Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
    Mader S; Jeganathan V; Arinuma Y; Fujieda Y; Dujmovic I; Drulovic J; Shimizu Y; Sakuma Y; Stern JNH; Aranow C; Mackay M; Yasuda S; Atsumi T; Hirohata S; Diamond B
    Arthritis Rheumatol; 2018 Feb; 70(2):277-286. PubMed ID: 29073350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
    Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
    Akaishi T; Takahashi T; Misu T; Kaneko K; Takai Y; Nishiyama S; Ogawa R; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakashima I
    Neurology; 2021 Jul; 97(1):e1-e12. PubMed ID: 33980704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.